Table 1. Noncovalent BTKi currently in... | American Society of Hematology

Table 1.

Noncovalent BTKi currently in clinical trials

Name	Number of patients with R/R CLL in pivotal trials	ORR, %	Median PFS	Median follow-up
Pirtobrutinib^22,23	252 (evaluable for response)	68	NR	9 mo
Nemtabrutinib²⁴	38 (evaluable for response)	57.9	NE	4.6 mo
Vecabrutinib^*⁴⁶	30	3	NE	28.5 wk^†

Name	Number of patients with R/R CLL in pivotal trials	ORR, %	Median PFS	Median follow-up
Pirtobrutinib^22,23	252 (evaluable for response)	68	NR	9 mo
Nemtabrutinib²⁴	38 (evaluable for response)	57.9	NE	4.6 mo
Vecabrutinib^*⁴⁶	30	3	NE	28.5 wk^†

Terminated.

Median time on treatment for patients with partial response/stable disease.

NE, not estimable; NR, not reached; R/R, relapsed/refractory.